Study of Anti-beta1AR and Anti-L-CaC Antibodies to Predict Outcomes in Adults with Dilated Cardiomyopathy

What this Trial Is About

Researchers are conducting a multicenter, prospective cohort study to understand the role of autoimmune reactions, specifically anti-beta1 adrenergic receptor anti-1AR and anti-L-type calcium channel anti-L-CaC antibodies, in patients with dilated cardiomyopathy DCM. The study aims to accurately evaluate how these antibodies relate to the prognosis of DCM, including risks such as cardiovascular death, ventricular tachycardia, and sudden death. This research will provide valuable epidemiological data and potential targets for future treatments for DCM. This study will follow 1,000 patients diagnosed with DCM across several centers in China for a period of three years. It focuses on measuring the prognostic value of these specific antibodies through regular assessments. Participants will be monitored for key health events such as all-cause death, heart transplantation, and rehospitalization for heart failure at multiple time points over the study period. During the study, participants will be followed up at months 1, 6, 12, 18, 24, and 36 to track clinical outcomes including death, heart transplant, heart failure rehospitalization, and sudden death. The study will gather detailed clinical information to assess the predictive value of the anti-1AR and anti-L-CaC antibodies in DCM progression and outcomes. This observational approach allows researchers to closely monitor the natural course of the disease and antibody impact over time.

Evaluating the Prognostic Impact of Anti-β1AR Antibodies and Anti-L-CaC Antibodies in Patients With Dilated Cardiomyopathy